Percutaneous radiofrequency ablation for pulmonary metastases from esophageal cancer: Retrospective evaluation of 21 patients

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose To evaluate retrospectively outcomes after radiofrequency (RF) ablation for pulmonary metastases from esophageal cancer.

Materials and Methods This study included 21 consecutive patients who met inclusion criteria (all men; mean age, 66.0 y) and had pulmonary metastases from esophageal cancer. There were 31 tumors (mean size, 1.7 cm) that were treated with 27 planned ablation sessions. At the initial RF ablation sessions, 3 patients had viable extrapulmonary recurrences, and 18 patients had viable recurrences confined to the lung. Primary study endpoints included patient survival and the determination of prognostic factors. Secondary endpoints included local efficacy and safety of the treatment. The log-rank test was used to identify prognostic factors. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.

Results Median follow-up duration after the initial RF ablation was 22.4 months (range, 6.2-76.1 mo). Estimated overall survival rates were 85.7% at 1 year, 54.8% at 2 years, and 38.4% at 3 years after the initial RF ablation session. The presence of viable extrapulmonary recurrences at the initial RF ablation session was an unfavorable prognostic factor (P

Conclusions RF ablation is a promising treatment option for patients with pulmonary metastases from esophageal cancer.

Original languageEnglish
Pages (from-to)1566-1572
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume25
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Esophageal Neoplasms
Neoplasm Metastasis
Lung
Recurrence
National Cancer Institute (U.S.)
Terminology
Survival Rate
Safety
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

@article{8e26be961e3e4ac6ba2641d5be145a67,
title = "Percutaneous radiofrequency ablation for pulmonary metastases from esophageal cancer: Retrospective evaluation of 21 patients",
abstract = "Purpose To evaluate retrospectively outcomes after radiofrequency (RF) ablation for pulmonary metastases from esophageal cancer.Materials and Methods This study included 21 consecutive patients who met inclusion criteria (all men; mean age, 66.0 y) and had pulmonary metastases from esophageal cancer. There were 31 tumors (mean size, 1.7 cm) that were treated with 27 planned ablation sessions. At the initial RF ablation sessions, 3 patients had viable extrapulmonary recurrences, and 18 patients had viable recurrences confined to the lung. Primary study endpoints included patient survival and the determination of prognostic factors. Secondary endpoints included local efficacy and safety of the treatment. The log-rank test was used to identify prognostic factors. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.Results Median follow-up duration after the initial RF ablation was 22.4 months (range, 6.2-76.1 mo). Estimated overall survival rates were 85.7{\%} at 1 year, 54.8{\%} at 2 years, and 38.4{\%} at 3 years after the initial RF ablation session. The presence of viable extrapulmonary recurrences at the initial RF ablation session was an unfavorable prognostic factor (P Conclusions RF ablation is a promising treatment option for patients with pulmonary metastases from esophageal cancer.",
author = "Yusuke Matsui and Takao Hiraki and Hideo Gobara and Hiroyasu Fujiwara and Toshihiro Iguchi and Yasuhiro Shirakawa and Toshiyoshi Fujiwara and Shinichi Toyooka and Susumu Kanazawa",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.jvir.2014.06.030",
language = "English",
volume = "25",
pages = "1566--1572",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Percutaneous radiofrequency ablation for pulmonary metastases from esophageal cancer

T2 - Retrospective evaluation of 21 patients

AU - Matsui, Yusuke

AU - Hiraki, Takao

AU - Gobara, Hideo

AU - Fujiwara, Hiroyasu

AU - Iguchi, Toshihiro

AU - Shirakawa, Yasuhiro

AU - Fujiwara, Toshiyoshi

AU - Toyooka, Shinichi

AU - Kanazawa, Susumu

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Purpose To evaluate retrospectively outcomes after radiofrequency (RF) ablation for pulmonary metastases from esophageal cancer.Materials and Methods This study included 21 consecutive patients who met inclusion criteria (all men; mean age, 66.0 y) and had pulmonary metastases from esophageal cancer. There were 31 tumors (mean size, 1.7 cm) that were treated with 27 planned ablation sessions. At the initial RF ablation sessions, 3 patients had viable extrapulmonary recurrences, and 18 patients had viable recurrences confined to the lung. Primary study endpoints included patient survival and the determination of prognostic factors. Secondary endpoints included local efficacy and safety of the treatment. The log-rank test was used to identify prognostic factors. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.Results Median follow-up duration after the initial RF ablation was 22.4 months (range, 6.2-76.1 mo). Estimated overall survival rates were 85.7% at 1 year, 54.8% at 2 years, and 38.4% at 3 years after the initial RF ablation session. The presence of viable extrapulmonary recurrences at the initial RF ablation session was an unfavorable prognostic factor (P Conclusions RF ablation is a promising treatment option for patients with pulmonary metastases from esophageal cancer.

AB - Purpose To evaluate retrospectively outcomes after radiofrequency (RF) ablation for pulmonary metastases from esophageal cancer.Materials and Methods This study included 21 consecutive patients who met inclusion criteria (all men; mean age, 66.0 y) and had pulmonary metastases from esophageal cancer. There were 31 tumors (mean size, 1.7 cm) that were treated with 27 planned ablation sessions. At the initial RF ablation sessions, 3 patients had viable extrapulmonary recurrences, and 18 patients had viable recurrences confined to the lung. Primary study endpoints included patient survival and the determination of prognostic factors. Secondary endpoints included local efficacy and safety of the treatment. The log-rank test was used to identify prognostic factors. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.Results Median follow-up duration after the initial RF ablation was 22.4 months (range, 6.2-76.1 mo). Estimated overall survival rates were 85.7% at 1 year, 54.8% at 2 years, and 38.4% at 3 years after the initial RF ablation session. The presence of viable extrapulmonary recurrences at the initial RF ablation session was an unfavorable prognostic factor (P Conclusions RF ablation is a promising treatment option for patients with pulmonary metastases from esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908122117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908122117&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2014.06.030

DO - 10.1016/j.jvir.2014.06.030

M3 - Article

C2 - 25156828

AN - SCOPUS:84908122117

VL - 25

SP - 1566

EP - 1572

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 10

ER -